MedTrace Logo

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

NCT03179501 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-10-22

No results posted yet for this study

Summary

This is a Phase 1 placebo-controlled biomarker study of NP001 in individuals with Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

NP001

NP001

DRUG

Placebo

Normal saline

Sponsors & Collaborators

  • Neuraltus Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Beau Nakamoto

    lead OTHER

Principal Investigators

  • Beau Nakamoto, MD PhD · University of Hawaii

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-07-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03179501 on ClinicalTrials.gov